• Proteins diagnostic of lung cancer up to 5 years before disease onset

    • Oncology
    • Read time: 5 minutes

    An earlier Olink to Science blog post covered some amazing research that found that certain blood protein biomarkers have the potential to predict cancer up to 3 years before diagnosis. This may also be the case for lung cancer, as detailed in a recent study by Dagnino and her colleagues, where elevated levels of CDCP1 were detected in participants of a cohort who later developed the disease.

    Chronic inflammation is a risk factor for the development of certain cancers, and cancer itself can also induce local inflammation, leading to tumor growth and metastasis. This inflammation can be seen as changes in the levels of cytokines and other proteins in the blood, and as such, these markers could make for ideal indicators of early cancer development. Past research has, however, only investigated a limited number of inflammatory markers or has been limited to analysis of plasma from participants with a short time to diagnosis.

    Proteins signals years before diagnosis

    Dagnino and colleagues sought to expand their analysis to a larger number of assays, as well as monitor participants for a longer period (16 years) to determine whether any inflammatory markers were already elevated more than 5 years before cancer diagnosis. The study used the Olink inflammation panel to analyze 92 proteins in 650 participants from 2 cohorts, the European Prospective Investigation into Cancer (EPIC), and the Norwegian Women and Cancer Study (NOWAC).

    Initial analysis revealed 12 proteins that were associated with increased risk of lung cancer in women, but most were not statistically significant when analyses were adjusted for smoking. More interestingly, elevated CDCP1 was also statistically significant in women who never smoked, as well as in both smoking and non-smoking men. Elevated levels of CDCP1 could be detected over 5 years before cancer diagnosis.

    Applicable to several cancer types

    The study sought to further elucidate the connection between CDCP1 and lung cancer risk by combining proteomic results with gene expression data. Correlation between blood levels of CDCP1 and levels of over 11610 gene transcripts suggested a significant association between CDCP1 and the expression of LRRN3 and SEM1. LRRN3 has been associated with smoking exposure in past research, which indicates that CDCP1 may play a role in smoking-induced lung cancer-related biological pathways. The analysis also suggested a strong association between CDCP1 and the WNT/B-catenin activation pathway, which has been linked to a wide variety of other cancers by activating genes involved in tumor development.

    ex-mark-icon-t_green

    The association between CDCP1 and lung cancer risk gives further indications of the biological mechanisms and pathways at play years before the disease manifests

    The results of this study suggest that CDCP1 may serve as an early indicator of lung cancer risk irrespective of smoking history. Moreover, the association between CDCP1 and lung cancer risk gives further indications of the biological mechanisms and pathways at play years before the disease manifests, further emphasizing the value of multiomics analysis. These last 4 blog posts have shown just how integral proteomics is to the progress of cancer research, and we at Olink are excited to see how much more we may contribute to this research space.

    blog-thumb-early detection of cancer

    Protein biomarkers are crucial in early detection of cancer

    Read the related blog post

    Reference:
    Dagnino et al. 2021, Prospective identification of elevated circulating CDCP1 in patients years before onset of lung cancer, Cancer Res. DOI: 10.1158/0008-5472.CAN-20-3454

    How the proteome behaves in healthy individuals

    Clinical research, Multiomics
    To achieve the goal of precision medicine, not only do different molecular profiles need to be understood in disease populations, but they must also be understood in the context of healthy populations.

    Key proteomics publications from 2020

    Proteomics
    Welcome to the first post of the all-new weekly Olink to Science! Our customer survey revealed that you would like to know more about the many publications, research, and other science happening at Olink, therefore this blog aims to do just that: keep you informed on the exciting science taking place with our technology.

    Protein biomarkers are crucial in early detection of cancer

    Clinical research, Oncology, Protein biomarkers
    A central premise of precision medicine is to identify biomarkers indicative of disease transitions early on. This is especially important in cancer where early treatment intervention could increase a patient’s chance of survival and reduce the probability of cancer recurrence.

    Using PEA and RNA-Seq to study disease pathology

    Clinical research, Proteomics
    The following study illustrates how transcriptomics and proteomics complement one another to clarify the pathology of a complex, and little understood disease. Atopic dermatitis (AD) is the most common chronic skin condition affecting up to 20% of children and 7-10% of adults, depending on the population.

    Olink protein biomarker panel indicates fermented foods fight inflammation

    Inflammation, Proteomics
    Could food be used to fight chronic disease?

    Study identifies proteins involved in immunotherapy response

    Oncology, Proteomics
    'Ultimately, it is all about understanding and treating patients better in the future.'

    Proteins diagnostic of lung cancer up to 5 years before disease onset

    Oncology
    An earlier Olink to Science blog post covered some amazing research that found that certain blood protein biomarkers have the potential to predict cancer up to 3 years before diagnosis. This may also be the case for lung cancer, as detailed in a recent study by Dagnino and her colleagues, where elevated levels of CDCP1 were detected in participants of a cohort who later developed the disease.

    Utilizing proteogenomics technology for novel drug target discovery

    Drug discovery & development
    High-throughput multiplexed proteomic technology is leading the way to the latest developments in pre-clinical disease analysis in drug discovery. The pharmaceutical industry is now increasing its efforts in the discovery of novel drug targets by using protein quantitative trait loci (pQTLs), which allows for a more confident inference of disease causality and associated protein regulation.

    Developing a high-performance biomarker panel for Alzheimer’s disease

    Clinical research, Neurology, Protein biomarkers
    A simple search of the term ‘scourge of Alzheimer’s Disease’ brings up over half a million website hits. A major disease, about 15% of us that reach the age of 67 to 74, and 44% of those 75 to 84 will develop AD.

    How proteomics helped diabetic kidney disease research advance

    Clinical research, Proteomics
    Dr. Krolewski and his team at the Harvard Medical School found 56 proteins to be significant in diabetic kidney disease patients. Potentially, these could serve as prognostic biomarkers for disease progression and treatment response. This is how adding proteomics to the methodologies elevated their research.